Brian Piekos is CFO at KalVista Pharmaceuticals, Inc. (KALV). They have made 5 open-market trades across 2 companies since 2021, most recently 2026-05-22.
CIK 0001815308
1 open-market purchase totalling $145K since 2021, against 4 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| KALV | 21,661 | $585K |
| GMTX | 17,615 | $238K |
| Total | $822K |
Shares reported on the most recent Form 4, priced at the 2026-05-26 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| KALV | SELL | 2026-05-22 | 2026-05-26 | $26.78 | $40K | +0.7% | N/A | N/A |
| KALV | SELL | 2026-04-17 | 2026-04-20 | $20.22 | $38K | +26.2% | +27.0% | N/A |
| KALV | SELL | 2026-02-23 | 2026-02-24 | $15.57 | $28K | +2.8% | +20.0% | +69.8% |
| KALV | SELL | 2025-11-24 | 2025-11-26 | $13.45 | $120K | +14.5% | +7.5% | +11.8% |
| GMTX | BUY | 2021-05-14 | 2021-05-18 | $9.46 | $145K | +8.6% | -1.9% | -68.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.